Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials

Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a... 1780 C.S.P. Lam et al. 14. Kang S-H, Park JJ, Choi D-J, Yoon C-H, Oh I-Y, Kang S-M, Yoo B-S, Jeon E-S, Kim 22. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez J-J, Cho M-C, Chae SC, Ryu K-H, Oh B-H. Prognostic value of NT-proBNP in AF, Butler J, Yancy CW, Fonarow GC. Outcomes in patients with heart failure heart failure with preserved versus reduced EF. Heart 2015;101:1881–1888. . with preserved, borderline, and reduced ejection fraction in the Medicare popu- 15. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, . lation. Am Heart J 2014;168:721–730.e3. Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and 23. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese short-term prognosis in acute destabilized heart failure: an international pooled G, Dahlstro ¨ m U, Lund LH. Significance of ischemic heart disease in patients with analysis of 1256 patients: the International Collaborative of NT-proBNP Study. . heart failure and preserved, midrange, and reduced ejection fraction: a nation- Eur Heart J 2006;27:330–337. wide cohort study. Circulation 2017;10:e003875. 16. van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen 24. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, JGP, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir in heart failure patients with preserved and reduced ejection fraction. J Am Coll . O, Logeart D, Dahlstro ¨ m U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Cardiol 2013;61:1498–1506. Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, 17. Cleland JGF,TaylorJ,FreemantleN,Goode KM,Rigby AS,Tendera M. Relationship Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; On behalf between plasma concentrations of N-terminal pro brain natriuretic peptide and the . of the Heart Failure Association of the European Society of Cardiology. characteristics and outcome of patients with a clinical diagnosis of diastolic heart fail- European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): ure: a report from the PEP-CHF study. Eur J Heart Fail 2012;14:487–494. 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, 18:613–625. McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of . 25. Lam CSP, Teng T-HK, Tay WT, Anand I, Zhang S, Shimizu W, Narasimhan C, baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions Park SW, Yu C-M, Ngarmukos T, Omar R, Reyes EB, Siswanto BB, Hung C-L, with irbesartan treatment effects in patients with heart failure and preserved Ling LH, Yap J, MacDonald M, Richards AM. Regional and ethnic differences ejection fraction: findings from the I-PRESERVE trial. Circulation 2011;4:569–577. . among patients with heart failure in Asia: the Asian sudden cardiac death in heart 19. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B- failure registry. Eur Heart J 2016;37:3141–3153. type natriuretic peptide levels and in-hospital mortality in acute decompensated 26. Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, heart failure. J Am Coll Cardiol 2007;49:1943–1950. Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B. 20. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. . The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart B-type natriuretic peptide strongly reflects diastolic wall stress in patients with Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial chronic heart failure: comparison between systolic and diastolic heart failure. (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC 2015;3: J Am Coll Cardiol 2006;47:742–748. . 429–441. 21. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, 27. Chioncel O, Mebazaa A, Harjola V-P, Coats AJ, Piepoli MF, Crespo-Leiro MG, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, EF, O’meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Miani D, Filippatos G, Maggioni AP; On behalf of the ESCHFL-TRI. Clinical phe- Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection . notypes and outcome of patients hospitalized for acute heart failure: the ESC fraction. N Engl J Med 2014;370:1383–1392. Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242–1254. doi:10.1093/eurheartj/ehx634 Corrigendum Online publish-ahead-of-print 26 October 2017 ................................................................................................ .................................................................. Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta- analysis of randomized trials [Eur Heart J (2017); doi:10.1093/eurheartj/ehx363]. The authors of the above article wish to inform readers that the following correction has been made post-publication: in the conclusion, the follow- ing sentence has been corrected to include the word ‘in’: ‘Results of this collaborative meta-analysis do not support the unselected use of active MCS in patients with CS complicating AMI.’ Published on behalf of the European Society of Cardiology. All rights reserved. V The Author 2017. For permissions, please email: journals.permissions@oup.com. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/20/1780/4566120 by Ed 'DeepDyve' Gillespie user on 17 June 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials

European Heart Journal , Volume Advance Article (20) – Oct 26, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/corrigendum-to-percutaneous-short-term-active-mechanical-support-56weYgD0Mh
Publisher
Oxford University Press
Copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
ISSN
0195-668X
eISSN
1522-9645
D.O.I.
10.1093/eurheartj/ehx634
Publisher site
See Article on Publisher Site

Abstract

1780 C.S.P. Lam et al. 14. Kang S-H, Park JJ, Choi D-J, Yoon C-H, Oh I-Y, Kang S-M, Yoo B-S, Jeon E-S, Kim 22. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez J-J, Cho M-C, Chae SC, Ryu K-H, Oh B-H. Prognostic value of NT-proBNP in AF, Butler J, Yancy CW, Fonarow GC. Outcomes in patients with heart failure heart failure with preserved versus reduced EF. Heart 2015;101:1881–1888. . with preserved, borderline, and reduced ejection fraction in the Medicare popu- 15. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, . lation. Am Heart J 2014;168:721–730.e3. Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and 23. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese short-term prognosis in acute destabilized heart failure: an international pooled G, Dahlstro ¨ m U, Lund LH. Significance of ischemic heart disease in patients with analysis of 1256 patients: the International Collaborative of NT-proBNP Study. . heart failure and preserved, midrange, and reduced ejection fraction: a nation- Eur Heart J 2006;27:330–337. wide cohort study. Circulation 2017;10:e003875. 16. van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen 24. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, JGP, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir in heart failure patients with preserved and reduced ejection fraction. J Am Coll . O, Logeart D, Dahlstro ¨ m U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Cardiol 2013;61:1498–1506. Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, 17. Cleland JGF,TaylorJ,FreemantleN,Goode KM,Rigby AS,Tendera M. Relationship Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; On behalf between plasma concentrations of N-terminal pro brain natriuretic peptide and the . of the Heart Failure Association of the European Society of Cardiology. characteristics and outcome of patients with a clinical diagnosis of diastolic heart fail- European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): ure: a report from the PEP-CHF study. Eur J Heart Fail 2012;14:487–494. 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, 18:613–625. McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of . 25. Lam CSP, Teng T-HK, Tay WT, Anand I, Zhang S, Shimizu W, Narasimhan C, baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions Park SW, Yu C-M, Ngarmukos T, Omar R, Reyes EB, Siswanto BB, Hung C-L, with irbesartan treatment effects in patients with heart failure and preserved Ling LH, Yap J, MacDonald M, Richards AM. Regional and ethnic differences ejection fraction: findings from the I-PRESERVE trial. Circulation 2011;4:569–577. . among patients with heart failure in Asia: the Asian sudden cardiac death in heart 19. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B- failure registry. Eur Heart J 2016;37:3141–3153. type natriuretic peptide levels and in-hospital mortality in acute decompensated 26. Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, heart failure. J Am Coll Cardiol 2007;49:1943–1950. Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B. 20. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. . The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart B-type natriuretic peptide strongly reflects diastolic wall stress in patients with Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial chronic heart failure: comparison between systolic and diastolic heart failure. (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC 2015;3: J Am Coll Cardiol 2006;47:742–748. . 429–441. 21. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, 27. Chioncel O, Mebazaa A, Harjola V-P, Coats AJ, Piepoli MF, Crespo-Leiro MG, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, EF, O’meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Miani D, Filippatos G, Maggioni AP; On behalf of the ESCHFL-TRI. Clinical phe- Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection . notypes and outcome of patients hospitalized for acute heart failure: the ESC fraction. N Engl J Med 2014;370:1383–1392. Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242–1254. doi:10.1093/eurheartj/ehx634 Corrigendum Online publish-ahead-of-print 26 October 2017 ................................................................................................ .................................................................. Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta- analysis of randomized trials [Eur Heart J (2017); doi:10.1093/eurheartj/ehx363]. The authors of the above article wish to inform readers that the following correction has been made post-publication: in the conclusion, the follow- ing sentence has been corrected to include the word ‘in’: ‘Results of this collaborative meta-analysis do not support the unselected use of active MCS in patients with CS complicating AMI.’ Published on behalf of the European Society of Cardiology. All rights reserved. V The Author 2017. For permissions, please email: journals.permissions@oup.com. Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/20/1780/4566120 by Ed 'DeepDyve' Gillespie user on 17 June 2018

Journal

European Heart JournalOxford University Press

Published: Oct 26, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off